Table 1.
Baseline characteristics of patients.
| Chronic hepatitis (n = 47) |
Comp LC (n = 26) |
Decomp LC (n = 11) |
HCC (n = 156) |
|
|---|---|---|---|---|
| Age (years) | 50.2 ± 12.2 | 57.7 ± 0.1 | 54.2 ± 4.9 | 59.1 ± 11.4 |
| Sex (M:F) | 23: 24 | 16: 10 | 7: 4 | 127 : 29 |
| AST (IU/L) | 56.7 ± 90.6 | 50.4 ± 38.9 | 120.3 ± 130.2 | 99.9 ± 105.4 |
| ALT (IU/L) | 69.7 ± 136.7 | 47.5 ± 60.2 | 73.6 ± 79.5 | 56.3 ± 48.2 |
| Total bilirubin (mg/dl) | 1.1 ± 0.6 | 1.3 ± 0.4 | 6.5 ± 8.8 | 2.1 ± 3.3 |
| Albumin (g/dl) | 4.2 ± 0.4 | 3.7 ± 0.5 | 3.1 ± 0.5 | 3.5 ± 0.6 |
| Prothrombin time (INR) | 1.1 ± 0.1 | 1.2 ± 0.1 | 1.6 ± 0.4 | 1.9 ± 9.2 |
| Etiology (n) | ||||
| HBV/HCV/Alcohol/others | 42/3/1/1 | 24/2/0/0 | 11/0/0/0 | 115/11/15/15 |
| Child-Pugh score | 5.2 ± 0.6 | 5.5 ± 0.8 | 8.2 ± 2.4 | 6.3 ± 1.7 |
| A/B/C | 44/3/0 | 24/2/0 | 3/4/4 | 102/41/13 |
| AFP (ng/ml)† | 2.8, 3.1 | 8.3, 16.8 | 18.7, 63.5 | 100.1, 1869.1 |
| Tumor size (cm) | 7.3 ± 4.8 | |||
| Total size (cm) | 9.9 ± 7.3 | |||
| Tumor number | 2.4 ± 1.56 | |||
| Portal vein thrombosis | 53 : 103 | |||
| Distant metastasis | 34 : 122 | |||
| VEGF (ng/ml) | 234.2 ± 242.6 | 133.5 ± 115.3 | 172.4 ± 68.1 | 273.7 ± 286.2 |
| b-FGF (pg/ml) | 8.9 ± 2.8 | 9.2 ± 2.4 | 9.1 ± 4.4 | 20.5 ± 13.2 |
| Thrombospondin-1 (ng/ml) | 132.4 ± 87.2 | 91.1 ± 60.6 | 126.7 ± 89.7 | 113.0 ± 95.7 |
| Endostatin (ng/ml) | 1.1 ± 0.5 | 1.0 ± 0.4 | 1.0 ± 0.4 | 1.5 ± 1.5 |
Comp LC, compensated liver cirrhosis; Decomp LC, decompensated liver cirrhosis; HCC, hepatocellular carcinoma; AST, aspartate aminotransaminase; ALT, alanine aminotransferase; INR, international normalized ratio; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, a-fetoprotein; VEGF, vascular endothelial growth factor; b-FGF, basic fibroblast growth factor.
†Kruskal-wallis test.